Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
|Videos|February 18, 2016
- Gastrointestinal Cancers: mCRC (Issue 7)
- Volume 1
- Issue 7
Dr. Katherine Van Loon on Recognizing Recurrences in Gastrointestinal Cancers
Author(s)Katherine Van Loon, MD
Van Loon says that oncologists need further research into how often and for how long patients with gastrointestinal cancers should be monitored.
Advertisement
Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco, discusses identifying recurrences in gastrointestinal cancers at a point where patients can receive further therapy.
Articles in this issue
over 10 years ago
Neoadjuvant Therapy Continues to Evolve for Pancreatic Cancerover 10 years ago
ERCC1 Expression Falls Short as Chemo Biomarker in mCRCover 10 years ago
Panitumumab Boosts Overall Survival in Chemorefractory mCRCover 10 years ago
Two Options Allows for Treatment Tailoring in Refractory CRCover 10 years ago
FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRCAdvertisement
Related to this article
The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.
New 177Lu-dotatate radioligand therapy expands options for SSTR+ GEP-NETs, backed by NETTER-1 efficacy and key safety guidance.
The FDA has recommended conducting a new trial showing an OS benefit with tovecimig in biliary cancer before submitting a BLA.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
5